Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroquinone + tretinoin versus hydroquinone for facial melasma (split-face, double-blind)
2025-521806-16-00Phase 2Authorised
- Sponsor
- mesoestetic Pharma Group
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hydroquinone and tretinoin in melasma (2 arms), sponsored by mesoestetic Pharma Group. Planned start Sep 2026; status: authorised.
02
Drugs
hydroquinonetretinoin
03
Conditions
melasma
Beyond the preview
Go deeper on 2025-521806-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521806-16-00.